Literature DB >> 25500259

MALT1 induced immune response is governed by miR-2909 RNomics.

Deepak Kaul1, M Arora2, A Garg2, S Sharma2.   

Abstract

The paracaspase mucosa-associated lymphoid tissue 1 (MALT1) has been widely recognized to play crucial role in lymphocyte activation, development and the generation of lymphomas through the modulation of innate and adaptive immune responses. Our results reported here provide evidence for the first time to support the view that MALT1 exerts its effect upon immune response involving genes coding for retinoic acid-inducible gene 1 (RIG1); interferon-β (IFN-β); apo-lipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G); IFN-γ; chemokine (C-C motif) ligand 5 (CCL5) and interleukin-17 (IL-17) through the initiation of cellular miR-2909 RNomics. This ensures sustained expression of specificity protein 1 (SP1)-dependent regulation of genes that in-turn governs MALT1 induced immune response. Based upon these results, a mechanistic-pathway is proposed that links the epigenomic-interplay between MALT1 and miR-2909.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CCL5; IL-17; KLF4; MALT1; PBMCs; miR-2909 RNomics

Mesh:

Substances:

Year:  2014        PMID: 25500259     DOI: 10.1016/j.molimm.2014.11.018

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  3 in total

1.  Cellular miR-2909 RNomics governs the genes that ensure immune checkpoint regulation.

Authors:  Deepak Kaul; Deepti Malik; Sameena Wani
Journal:  Mol Cell Biochem       Date:  2018-06-20       Impact factor: 3.396

Review 2.  Apolipoprotein B mRNA editing enzyme catalytic polypeptide-like family genes activation and regulation during tumorigenesis.

Authors:  Jianlong Gao; Hani Choudhry; Wei Cao
Journal:  Cancer Sci       Date:  2018-06-28       Impact factor: 6.716

3.  Human cellular mitochondrial remodelling is governed by miR-2909 RNomics.

Authors:  Deepti Malik; Deepak Kaul
Journal:  PLoS One       Date:  2018-09-25       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.